about
Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemiaLessons for the clinic from rituximab pharmacokinetics and pharmacodynamicsAssociation study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patientsPre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in miceGlutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with CyclophosphamideIn Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaStructural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study.The safety profile of cyclophosphamide in multiple sclerosis therapy.Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma CommitteePharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report.Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic indexRelative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducersThe cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells.Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose.The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeIslamic fasting and multiple sclerosis.Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivoCyclophosphamide-Induced Morphological Changes in Dental Root Development of ICR Mice.Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory studyImmunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model.Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitisPharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer managementHigh exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapyCase Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part ITreatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care planFluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation.Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology GroupThe role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors.A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.Predicting and preventing the cardiotoxicity of cancer therapy.Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients.Management of hematological malignancies in patients affected by renal failure.Current and future treatment approaches for neuromyelitis optica.Genetic variations in multiple myeloma II: association with effect of treatment.Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants.Induction of cytochrome P450 enzymes: a view on human in vivo findings.
P2860
Q24198941-174151B6-C756-4B16-98AC-80F9DB7B6661Q26849243-8B049821-6AFF-4216-BC7E-4C7DC3AC8F64Q28255901-E4AC4715-CCD0-4595-86B2-27269FCA813AQ28486646-56852FD2-7E18-4828-933F-ADFA14736793Q28550922-35F70D36-A019-4E3D-9C1C-C4A02BE0260AQ28554677-5CEF55A1-867D-49B3-B57F-7F9683FE1E22Q30396630-474C272B-D90E-4952-A4AE-9E7EFE071774Q30418239-96C4D090-6A2C-402E-BF39-33F0D0D79F55Q31105891-86A233B2-6C4D-4C68-B552-5F8119A7CADAQ33396263-F00E3F81-8FE1-4A70-9F2C-4FF40A9DD2C2Q33427666-0AB9C3D7-E4FC-40C9-AC69-ADD1E8729497Q33646358-57325853-4F14-4F7D-BE73-EA669C183837Q33718131-1CFA372E-372F-4A04-8EED-A72ECBC04C6BQ33881813-1CFABF47-B543-4C93-97DE-8ABFECACCF7DQ33892820-338DF0A0-D57A-4D83-A33F-91027C5C1F5DQ34118894-4F61244E-1CC8-4A65-AFCD-CFC2904BDCDBQ34457423-392F3076-848D-492D-9510-76C2AF51C1D2Q34824471-2FEF27DD-5441-42F9-983A-7B85FE67A790Q35127335-EDF24535-74A0-48DA-BA4C-F8059B5E89B5Q35647150-6D8A3A4A-73A8-4461-A5C9-6FB066949AA8Q35694561-7AF39D1D-5D7F-4A4E-A5BA-7FEB99EFC0C7Q35886589-5AA8133D-FC9C-4990-AA4C-8F44611D7F22Q36221386-68991B9B-1CEC-4EDF-A3F3-DB7F92C09F3AQ36336024-F0C48FE2-F38C-426E-8C41-2619693827DFQ36441485-1D2636A9-5C73-4423-B47D-4CA9C6F0BA3EQ36614634-D8B4E986-4038-462D-AFE1-C971A45612B9Q36757071-04C42613-D58F-4E31-8170-731B8AC40A28Q36777599-BC7569AF-A4E0-4ACE-B2A4-70594E5DC040Q36797109-E87CBA93-9C10-4931-B509-04B24B0145FBQ36949557-800F1AA5-D5CC-4349-807B-14008715EC39Q37120672-5504DA54-B2F9-4BC1-ADB6-7C4CAF9AB4CDQ37185367-7B9573E2-E902-4CB0-8144-9E47F9EA0FE7Q37206443-143A56C9-8F63-478E-9412-D0802FFD4E13Q37230408-327E0FC3-FF70-4495-AEE9-3336F4F83760Q37684587-61FE1F7D-1BB5-4B39-863D-A30BD47854A2Q37854710-3686E9DA-4B0B-4482-8D49-31A131687B0BQ37892874-C9781E72-BCDB-4172-BE62-37D105353C4CQ37924890-A41E50D5-AC35-41EF-94FB-9FED538AE464Q38003177-02E3713D-C723-42AB-A3BB-DF2C7AE86926Q38057372-C7CC3834-9C23-4865-8357-64CDADEA6C9D
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Clinical pharmacokinetics of cyclophosphamide.
@ast
Clinical pharmacokinetics of cyclophosphamide.
@en
type
label
Clinical pharmacokinetics of cyclophosphamide.
@ast
Clinical pharmacokinetics of cyclophosphamide.
@en
prefLabel
Clinical pharmacokinetics of cyclophosphamide.
@ast
Clinical pharmacokinetics of cyclophosphamide.
@en
P2093
P1476
Clinical pharmacokinetics of cyclophosphamide.
@en
P2093
Alwin D R Huitema
Jos H Beijnen
Milly E de Jonge
Sjoerd Rodenhuis
P304
P356
10.2165/00003088-200544110-00003
P577
2005-01-01T00:00:00Z
P5875
P6179
1004413641